Representative Matters
Back to all Representative Matters
Representative Matter

Cybin Inc. Completes Acquisition of Small Pharma Inc.

Richard M. Kimel, Marek Lorenc, Manjit Singh, Ryan Cohen, Nadia S. Narain and Joshua Ward

On October 23, 2023, Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, and Small Pharma Inc. (TSXV: DMT), a U.K.-based biotechnology company focused on short-duration psychedelic therapies for mental conditions, announced the completion of Cybin's acquisition of all of Small Pharma's issued and outstanding securities pursuant to a court-approved statutory plan of arrangement under the Business Corporations Act (British Columbia).

The combined company resulting from the arrangement is expected to create an international clinical-stage leader in novel psychedelic therapeutics. The arrangement was effected pursuant to the terms of an arrangement agreement dated August 28, 2023, between Cybin and Small Pharma.

Aird & Berlis represented Small Pharma with a team led by Richard Kimel and including Marek Lorenc, Ryan Cohen, Nadia Narain (Corporate/Securities) and Manjit Singh (Tax).

Related Areas of Expertise

Industries

Representative Matters